Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate‐adjusted analysis at the pre‐adjuvant chemotherapy timing

Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate‐adjusted analysis at the pre‐adjuvant chemotherapy timing

Abstract Background The pre‐adjuvant chemotherapy (PAC) status of postoperative pancreatic ductal adenocarcinoma (PDAC) patients has not been studied and elaborated well previously. Method The association of PAC variables and prognoses was explored using a multivariable Cox model, restricted cubic s...

Full description

Bibliographic Details
Main Authors: Ningzhen Fu, Kai Qin, Jingfeng Li, Jiabin Jin, Yu Jiang, Xiaxing Deng, Baiyong Shen
Format: Article
Language:English
Published: Wiley 2022-09-01
Series:Cancer Medicine
Subjects:
chemotherapy completeness (CHC)
fasting blood glucose
FBG
pancreatic ductal adenocarcinoma (PDAC)
pre‐adjuvant chemotherapy (PAC)
sarcopenia
Online Access:https://doi.org/10.1002/cam4.4698

Similar Items

Similar Items